Eyepoint Pharmaceuticals Inc (EYPT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eyepoint Pharmaceuticals Inc (EYPT) has a cash flow conversion efficiency ratio of -0.297x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-59.35 Million) by net assets ($200.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Eyepoint Pharmaceuticals Inc for the company's overall valuation and market capitalisation.
Eyepoint Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Eyepoint Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Eyepoint Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eyepoint Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore Eyepoint Pharmaceuticals Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Biodesix Inc
NASDAQ:BDSX
|
-0.171x |
|
XinJiang GuoTong Pipeline Co Ltd
SHE:002205
|
-0.121x |
|
Shanghai Hile Bio-tech
SHG:603718
|
-0.001x |
|
Legato Merger Corp. III
NYSE MKT:LEGT
|
-0.001x |
|
Molson Coors Canada Inc
TO:TPX-B
|
0.079x |
|
Zorlu Enerji Elektrik Uretim AS
IS:ZOREN
|
-0.009x |
|
WATERDROP INC.ADS/10 CL.A
F:717
|
N/A |
|
Optimum Communications, Inc.
NYSE:OPTU
|
-0.041x |
Annual Cash Flow Conversion Efficiency for Eyepoint Pharmaceuticals Inc (2002–2024)
The table below shows the annual cash flow conversion efficiency of Eyepoint Pharmaceuticals Inc from 2002 to 2024. View Eyepoint Pharmaceuticals Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $336.50 Million | $-126.23 Million | -0.375x | -5428.07% |
| 2023-12-31 | $266.32 Million | $1.88 Million | 0.007x | +101.04% |
| 2022-12-31 | $96.37 Million | $-65.00 Million | -0.675x | -148.27% |
| 2021-12-31 | $184.38 Million | $-50.10 Million | -0.272x | +65.10% |
| 2020-12-31 | $18.54 Million | $-14.44 Million | -0.779x | +88.56% |
| 2019-12-31 | $8.33 Million | $-56.70 Million | -6.807x | -263.12% |
| 2018-12-31 | $11.69 Million | $-21.91 Million | -1.874x | -22.00% |
| 2017-12-31 | $13.34 Million | $-20.49 Million | -1.536x | -96.63% |
| 2016-12-31 | $20.88 Million | $-16.32 Million | -0.781x | -277.33% |
| 2015-12-31 | $23.37 Million | $10.30 Million | 0.441x | +161.63% |
| 2014-12-31 | $14.92 Million | $-10.67 Million | -0.715x | +37.04% |
| 2013-12-31 | $7.70 Million | $-8.74 Million | -1.136x | -72.05% |
| 2012-12-31 | $13.64 Million | $-9.00 Million | -0.660x | -679.47% |
| 2011-12-31 | $37.43 Million | $-3.17 Million | -0.085x | -128.27% |
| 2010-12-31 | $33.04 Million | $9.90 Million | 0.300x | +183.60% |
| 2009-12-31 | $23.54 Million | $-8.44 Million | -0.358x | -51.84% |
| 2008-12-31 | $21.79 Million | $-5.14 Million | -0.236x | +26.68% |
| 2007-12-31 | $65.91 Million | $-21.21 Million | -0.322x | -32.04% |
| 2006-12-31 | $66.20 Million | $-16.14 Million | -0.244x | -58.47% |
| 2005-12-31 | $60.74 Million | $-9.34 Million | -0.154x | 0.00% |
| 2004-12-31 | $60.74 Million | $-9.34 Million | -0.154x | +24.42% |
| 2003-12-31 | $26.70 Million | $-5.44 Million | -0.204x | +71.85% |
| 2002-12-31 | $4.23 Million | $-3.06 Million | -0.723x | -- |
About Eyepoint Pharmaceuticals Inc
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib… Read more